28 / 30
243 non-synonymous mutations
TMB: Tumor Mutation Burden
100
90
80
70
60
50
40
30
20
10
0
0
3
6
9
12
Months
15
18
21
24
PFS (%)
High
Low
Medium
Medium
n = 49
n = 47
3.6
(2.7, 6.9)
Low
n = 62
4.2
(1.5, 5.6)
9.7
(5.1, NR)
Median PFS, months
(95% CI)
High
Nivolumab Arm
Months
Carbone, DP et al. NEJM 2017
TMB and PD-L1 and efficacy of
1st line Nivolumab in advanced
NSCLC (CheckMate026 trial)